NMT.001 / NEUmiRNA Therapeutics - LARVOL DELTA

Angelini Ventures co-leads €20 million Series A financing in Neumirna Therapeutics to Develop Next-Generation RNA Therapeutics for Epilepsy and other Neurological Disorders (GlobeNewswire) - "Angelini Ventures..today announces that it has co-led a €20 million Series A financing round in Neumirna Therapeutics, an RNA-focused biotech company developing next-generation therapeutics for neurological disorders...The proceeds of the Series A financing will enable Neumirna to advance its lead asset NMT.001 for the treatment of epilepsy into clinical development bringing NMT.001 towards clinical validation. Proceeds will also expand its R&D capabilities and scale its pioneering platform."

Financing • CNS Disorders • Epilepsy